JP2017533263A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533263A5
JP2017533263A5 JP2017540961A JP2017540961A JP2017533263A5 JP 2017533263 A5 JP2017533263 A5 JP 2017533263A5 JP 2017540961 A JP2017540961 A JP 2017540961A JP 2017540961 A JP2017540961 A JP 2017540961A JP 2017533263 A5 JP2017533263 A5 JP 2017533263A5
Authority
JP
Japan
Prior art keywords
alkyl
group
diyl
substituted
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017540961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533263A (ja
JP6499306B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/021417 external-priority patent/WO2016064445A1/en
Publication of JP2017533263A publication Critical patent/JP2017533263A/ja
Publication of JP2017533263A5 publication Critical patent/JP2017533263A5/ja
Application granted granted Critical
Publication of JP6499306B2 publication Critical patent/JP6499306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017540961A 2014-10-24 2015-03-19 ランチオニンシンテターゼｃ様２系治療薬 Active JP6499306B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462068322P 2014-10-24 2014-10-24
US62/068,322 2014-10-24
US201562101164P 2015-01-08 2015-01-08
US62/101,164 2015-01-08
PCT/US2015/021417 WO2016064445A1 (en) 2014-10-24 2015-03-19 Lanthionine synthetase c-like 2-based therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019046867A Division JP6806829B2 (ja) 2014-10-24 2019-03-14 ランチオニンシンテターゼｃ様２系治療薬

Publications (3)

Publication Number Publication Date
JP2017533263A JP2017533263A (ja) 2017-11-09
JP2017533263A5 true JP2017533263A5 (OSRAM) 2018-04-26
JP6499306B2 JP6499306B2 (ja) 2019-04-10

Family

ID=52811239

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017540961A Active JP6499306B2 (ja) 2014-10-24 2015-03-19 ランチオニンシンテターゼｃ様２系治療薬
JP2019046867A Active JP6806829B2 (ja) 2014-10-24 2019-03-14 ランチオニンシンテターゼｃ様２系治療薬
JP2020201503A Pending JP2021073170A (ja) 2014-10-24 2020-12-04 ランチオニンシンテターゼｃ様２系治療薬

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019046867A Active JP6806829B2 (ja) 2014-10-24 2019-03-14 ランチオニンシンテターゼｃ様２系治療薬
JP2020201503A Pending JP2021073170A (ja) 2014-10-24 2020-12-04 ランチオニンシンテターゼｃ様２系治療薬

Country Status (21)

Country Link
US (9) US9556146B2 (OSRAM)
EP (2) EP3209655B1 (OSRAM)
JP (3) JP6499306B2 (OSRAM)
KR (3) KR102134171B1 (OSRAM)
CN (2) CN107108573B (OSRAM)
AU (3) AU2015337091B2 (OSRAM)
BR (1) BR112017008416B1 (OSRAM)
CA (1) CA2965472C (OSRAM)
DK (1) DK3209655T3 (OSRAM)
ES (1) ES2822987T3 (OSRAM)
HR (1) HRP20201416T1 (OSRAM)
HU (1) HUE051299T2 (OSRAM)
IL (2) IL252630B (OSRAM)
LT (1) LT3209655T (OSRAM)
NZ (1) NZ732213A (OSRAM)
PL (1) PL3209655T3 (OSRAM)
PT (1) PT3209655T (OSRAM)
RS (1) RS61013B1 (OSRAM)
RU (3) RU2688677C2 (OSRAM)
SI (1) SI3209655T1 (OSRAM)
WO (1) WO2016064445A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61013B1 (sr) * 2014-10-24 2020-11-30 Landos Biopharma Inc Terapeutski preparati zasnovani na lantionin sintetazi c- sličnom proteinu-2
US11529354B2 (en) 2017-09-05 2022-12-20 President And Fellows Of Harvard College Methods and compositions for the treatment of tuberculosis
WO2019099426A1 (en) * 2017-11-17 2019-05-23 Icahn School Of Medicine At Mount Sinai Influenza virus inhibitor targeting nucleoprotein
CA3083442A1 (en) 2017-11-30 2019-06-06 Landos Biopharma, Inc. Therapies with lanthionine c-like protein 2 ligands and cells prepared therewith
JP7458406B2 (ja) 2018-12-21 2024-03-29 セルジーン コーポレーション Ｒｉｐｋ２のチエノピリジン阻害剤
CA3135502C (en) 2019-12-20 2024-01-09 Josep Bassaganya-Riera Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same
US12234578B2 (en) 2020-01-29 2025-02-25 Wisconsin Alumni Research Foundation Tannin composite fibers
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US20240101552A1 (en) 2020-09-18 2024-03-28 Shanghai Pharmaceuticals Holding Co., Ltd. Carbonyl heterocyclic compound and application thereof
WO2022057932A1 (zh) * 2020-09-18 2022-03-24 上海医药集团股份有限公司 一种羰基杂环类化合物及其应用
US11459310B2 (en) 2020-10-22 2022-10-04 Landos Biopharma, Inc. LANCL ligands
CA3196954A1 (en) 2020-11-03 2022-05-12 Josep Bassaganya-Riera Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators
CA3197934A1 (en) 2020-11-19 2022-05-27 Nimmune Biopharma, Inc. Compounds, compositions, and methods for treating inflammatory or immune-mediated conditions of surface tissues
WO2022127774A1 (zh) * 2020-12-15 2022-06-23 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
CN113908256B (zh) * 2021-11-26 2023-05-26 中国农业科学院兰州兽医研究所 Lancl1蛋白在制备抗病毒药物中的应用
WO2024155555A1 (en) * 2023-01-16 2024-07-25 Nimml Institute Neuroprotective compounds for therapeutic use

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282643A3 (en) 1986-11-22 1990-08-22 The Green Cross Corporation Use of pharmaceutical compositions comprising cyclohexane derivatives in the treatment or prevention of peptic ulcers
BR9510521A (pt) * 1994-12-23 1998-07-14 Smithkline Beecham Corp Monômeros de ciclohexan-1-ona 4,4-disubstituída e compostos relacionados
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
AU4471497A (en) * 1996-10-11 1998-05-11 Kowa Co. Ltd. Novel diamide compounds and drugs containing the same
DE69828998T2 (de) * 1997-12-24 2006-05-04 Nikem Research S.R.L., Baranzate Di Bollate Indolderivate verwendbar zur behandlung von u.a. osteoporosis
AU2654399A (en) 1998-02-02 1999-08-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
JP2001247550A (ja) * 1999-12-27 2001-09-11 Japan Tobacco Inc 縮合環化合物及びその医薬用途
CA2401489A1 (en) * 2000-03-02 2001-09-07 Ichiro Miki Oxygen-containing heterocyclic compounds
US20090124690A1 (en) 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
US6734191B2 (en) 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
RU2297413C2 (ru) * 2000-09-15 2007-04-20 Анормед, Инк. Гетероциклические соединения, моделирующие активность хемокинового рецептора, их применение и содержащая их фармацевтическая композиция
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
WO2005037269A1 (ja) 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
WO2005082905A1 (ja) * 2004-02-26 2005-09-09 Kyowa Hakko Kogyo Co., Ltd. 二環性複素環化合物
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
EP1814393A4 (en) 2004-11-04 2010-02-03 Med College Georgia Res Inst TOLEROGENIC VACCINATE AND METHOD
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
PL1861387T3 (pl) 2005-01-28 2014-08-29 Dae Woong Pharma Pochodne benzoimidazolu i ich kompozycje farmaceutyczne
GB0508314D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
CN100434419C (zh) 2005-06-03 2008-11-19 中国人民解放军军事医学科学院毒物药物研究所 单环多取代饱和环已酮类化合物及其制备方法和用途
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
WO2007010964A1 (ja) 2005-07-22 2007-01-25 Shionogi & Co., Ltd. Ｐｇｄ２受容体アンタゴニスト活性を有するインドール誘導体
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
WO2007019416A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US8143285B2 (en) 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
ES2625378T3 (es) 2005-09-27 2017-07-19 Shionogi & Co., Ltd. Derivado de sulfonamida que tiene actividad antagonista del receptor de PGD2
UY29825A1 (es) 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US7741367B2 (en) 2006-02-08 2010-06-22 Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat diseases and disorders
US8367727B2 (en) 2006-02-08 2013-02-05 Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat diseases and disorders
JP2008056615A (ja) 2006-08-31 2008-03-13 Fujifilm Corp ビニルエチニルアリールカルボン酸類、その製造方法及びそれを用いた熱架橋性化合物の製造方法
WO2008061373A1 (en) 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and similar diseases
US7795249B2 (en) 2006-12-22 2010-09-14 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
WO2008092006A2 (en) 2007-01-24 2008-07-31 Cernofina, Llc Antimicrobial compositions
MY146643A (en) 2007-07-30 2012-09-14 Dae Woong Pharma Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
WO2009067600A2 (en) 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating inflammation
CN103351390A (zh) 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
US8354401B2 (en) 2008-10-27 2013-01-15 Mitsubishi Tanabe Pharma Corporation Oxazolidinone amide aromatic compounds for supressing MMP-9 production
CA2740195A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
CA2647900C (en) 2008-12-23 2017-05-16 National Research Council Of Canada Inhibitors of a 9-cis-epoxycarotenoid dioxygenase
WO2010121046A1 (en) 2009-04-17 2010-10-21 Janssen Pharmaceutica Nv 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
US9062564B2 (en) * 2009-07-31 2015-06-23 General Electric Company Solvent based slurry compositions for making environmental barrier coatings and environmental barrier coatings comprising the same
KR101804588B1 (ko) * 2009-10-13 2017-12-04 리간드 파마슈티칼스 인코포레이티드 조혈 성장 인자 모방체 소분자 화합물 및 이의 용도
DE102009057167A1 (de) 2009-12-05 2011-06-09 Merck Patent Gmbh Elektronische Vorrichtung enthaltend Metallkomplexe
JP2011246461A (ja) 2010-04-27 2011-12-08 Mitsubishi Tanabe Pharma Corp 新規アミド誘導体を含有する医薬組成物
WO2011140215A2 (en) * 2010-05-04 2011-11-10 Virginia Tech Intellectual Properties, Inc. Lanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders
WO2011150160A2 (en) 2010-05-26 2011-12-01 Virginia Tech Intellectual Properties, Inc. Method of preventing and treating inflammatory diseases and disorders with abscisic acid
TW201211027A (en) 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
KR101743280B1 (ko) 2010-06-17 2017-06-02 얀센 파마슈티카 엔.브이. Ccr2의 사이클로헥실-아제티디닐 길항제
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
KR20120035285A (ko) 2010-10-05 2012-04-16 에스케이이노베이션 주식회사 셀룰로오스아세테이트 필름
CA2861939A1 (en) 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators
CN103709115A (zh) 2012-10-09 2014-04-09 山东亨利医药科技有限责任公司 截短侧耳素类抗生素衍生物
ES2654093T3 (es) 2013-03-13 2018-02-12 Inflammatory Response Research, Inc. Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
JP6150701B2 (ja) 2013-09-30 2017-06-21 キヤノン株式会社 電子写真感光体、プロセスカートリッジおよび電子写真装置
RS61013B1 (sr) * 2014-10-24 2020-11-30 Landos Biopharma Inc Terapeutski preparati zasnovani na lantionin sintetazi c- sličnom proteinu-2

Similar Documents

Publication Publication Date Title
JP2017533263A5 (OSRAM)
RU2017117562A (ru) Лекарственные средства на основе лантионинсинтетаза с-подобного белка
JP2019524883A5 (OSRAM)
JP2012092103A5 (OSRAM)
JP2016503797A5 (OSRAM)
JP2013537203A5 (OSRAM)
JP2015500843A5 (OSRAM)
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
JP2015520140A5 (OSRAM)
JP2014521625A5 (OSRAM)
JP2016530259A5 (OSRAM)
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
JP2016515561A5 (OSRAM)
JP2015535847A5 (OSRAM)
JP2013063963A5 (ja) 複素環化合物
JP2015522650A5 (OSRAM)
JP2015535839A5 (OSRAM)
JP2016505637A5 (OSRAM)
JP2015051983A5 (OSRAM)
JP2016531126A5 (OSRAM)
JP2015508092A5 (OSRAM)
JP2014530838A5 (OSRAM)
JP2018501215A5 (OSRAM)
JP2017531663A5 (OSRAM)
JP2017513852A5 (OSRAM)